BHC Bausch Health Companies (BHC) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000885590
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
100
13F, latest reported quarter
What the filings say about BHC
Insiders, 180 days
-$391.7K net sold
2 sellers · 50% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$258.9K
1 notice
Bausch Health Companies insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Bausch Health Companies Inc. insiders sold a net $391.7K of stock across 40 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 11.0% of the 334,853 shares held after it.
- No other insider sold within 30 days.
- 100 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, US Pharma Lenar Aimee J. sold about $258.9K of BHC under a 10b5-1 plan on Aug 19, 2026, the largest insider sale at the company on our record; 100 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Aug 21, 2025.
- The trade is 49.6% of the 49,339 shares held after it.
- No other insider sold within 30 days.
- 100 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Lee Frank D. sold about $132.8K of BHC on May 19, 2026, the largest insider sale at the company since 2022; 100 funds added in the latest 13F quarter.Context
- 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Mar 2, 2026.
- The trade is 0.7% of the 616,761 shares held after it.
- No other insider sold within 30 days.
- 100 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, General Counsel Carson Seana sold about $25.5K of BHC on Mar 3, 2026; 100 funds added in the latest 13F quarter.Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Feb 27, 2026.
- The trade is 0.9% of the 776,076 shares held after it.
- No other insider sold within 30 days.
- 100 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, General Counsel Carson Seana sold about $39.6K of BHC on Mar 2, 2026; 100 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Sep 8, 2025.
- The trade is 1.0% of the 809,258 shares held after it.
- No other insider sold within 30 days.
- 100 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, General Counsel Carson Seana sold about $49.9K of BHC on Feb 27, 2026; 100 funds added in the latest 13F quarter.40 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$391.7K over 180 days
-$258.9K over 90 days
below 54% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
100 funds bought in last quarter
more than 68% of Pharma & Biotech
Revenue
+6.7% year over year
more than 55% of Pharma & Biotech
Margin
1.5% net margin
more than 75% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
3.2% of the float short (float per yahoo 2026-10-26) · 4.8 days to cover · settled 2026-09-30
below 64% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch BHC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-1.1%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns BHC: institutional holders (13F)
13F holdings, latest reported quarter
73,255,869 sh
$361.2M
34,665,731 sh
$170.7M
10,832,582 sh
$53.4M
8,000,000 sh
$39.4M
7,465,468 sh
$36.8M
Congress trades in BHC
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
BHC planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Lenar Aimee J.
Filed 2026-08-19
$258.9K
BHC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Shelton International Select Equity Fund
$212.6K position · as of 2026-06-30
0.5%
Sparkline International Intangible Value ETF
$58.8K position · as of 2026-05-29
0.3%
The Canadian Small Company Series
$5.6M position · as of 2026-07-31
0.3%
VOYA MULTI-MANAGER INTERNATIONAL SMALL CAP FUND
$1.3M position · as of 2026-07-31
0.2%
Federated Hermes Opportunistic High Yield Bond Fund
$473.5K position · as of 2026-05-31
0.1%
VanEck Pharmaceutical ETF
$860.9K position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Joseph CPapa
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2021
$22.9M
$37.1M
$6.0M
-8%
+26%
2020
$14.1M
-$10.6M
$4.3M
-30%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $391.7K sold by insiders over 180 days, 100 funds added last quarter, $258.9K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
BHC financials
Revenue growth
+6.7%
XBRL, annual
Net margin
1.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$10.9B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM BHC
| FY Dec 2025 | $10.3B |
| FY Dec 2024 | $9.6B |
| FY Dec 2023 | $8.8B |
| FY Dec 2022 | $8.1B |
| FY Dec 2021 | $8.4B |
| Jun 2026 | $2.9B |
| Mar 2026 | $2.5B |
| Dec 2025 | $2.8B |
| Sep 2025 | $2.7B |
| Jun 2025 | $2.5B |
| Mar 2025 | $2.3B |
| Dec 2024 | $2.6B |
| Sep 2024 | $2.5B |
At each fiscal year end
Single quarter
Net margin, TTM
-10.1%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM BHC
| FY Dec 2025 | +1.5% |
| FY Dec 2024 | -0.5% |
| FY Dec 2023 | -6.8% |
| FY Dec 2022 | -2.8% |
| FY Dec 2021 | -11.2% |
| Jun 2026 | +9.0% |
| Mar 2026 | -56.4% |
| Dec 2025 | -4.0% |
| Sep 2025 | +6.7% |
| Jun 2025 | +5.8% |
| Mar 2025 | -2.6% |
| Dec 2024 | +3.6% |
| Sep 2024 | -3.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$1.4B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM BHC
| FY Dec 2025 | $1.0B |
| FY Dec 2024 | $1.3B |
| FY Dec 2023 | $817.0M |
| FY Dec 2022 | -$946.0M |
| FY Dec 2021 | $1.2B |
| Jun 2026 | $593.0M |
| Mar 2026 | $121.0M |
| Dec 2025 | $403.0M |
| Sep 2025 | $314.0M |
| Jun 2025 | $190.0M |
| Mar 2025 | $96.0M |
| Dec 2024 | $495.0M |
| Sep 2024 | $334.0M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity BHC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.09x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt BHC
| FY Dec 2025 | 0.07x |
| FY Dec 2024 | 0.07x |
| FY Dec 2023 | 0.05x |
| FY Dec 2022 | -0.04x |
| FY Dec 2021 | 0.06x |
| Jun 2026 | 0.09x |
| Mar 2026 | 0.07x |
| Dec 2025 | 0.07x |
| Sep 2025 | 0.07x |
| Jun 2025 | 0.07x |
| Mar 2025 | 0.07x |
| Dec 2024 | 0.07x |
| Sep 2024 | 0.06x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity BHC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -442.0% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-4.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets BHC
| FY Dec 2025 | +0.6% |
| FY Dec 2024 | -0.2% |
| FY Dec 2023 | -2.2% |
| FY Dec 2022 | -0.8% |
| FY Dec 2021 | -3.1% |
| Jun 2026 | -4.2% |
| Mar 2026 | -4.7% |
| Dec 2025 | +0.6% |
| Sep 2025 | +1.4% |
| Jun 2025 | +0.4% |
| Mar 2025 | -0.1% |
| Dec 2024 | -0.2% |
| Sep 2024 | -0.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital BHC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | +6.1% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+4.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed BHC
| FY Dec 2025 | +8.6% |
| FY Dec 2024 | +7.2% |
| FY Dec 2023 | +4.3% |
| FY Dec 2022 | +2.0% |
| FY Dec 2021 | +1.8% |
| Jun 2026 | +4.2% |
| Mar 2026 | +2.8% |
| Dec 2025 | +8.6% |
| Sep 2025 | +8.6% |
| Jun 2025 | +7.2% |
| Mar 2025 | +6.9% |
| Dec 2024 | +7.2% |
| Sep 2024 | +6.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing BHC
| FY Dec 2025 | 16.55x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 16.55x |
| Sep 2025 | 6.65x |
| Jun 2025 | 25.62x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$21.3B
market value at close 2026-10-27 on 2026-07-24 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value BHC
| FY Dec 2025 | $22.1B |
| FY Dec 2024 | $23.4B |
| FY Dec 2023 | $24.4B |
| FY Dec 2022 | $22.5B |
| FY Dec 2021 | $32.0B |
| Jun 2026 | $20.8B |
| Mar 2026 | $21.5B |
| Dec 2025 | $22.1B |
| Sep 2025 | $22.1B |
| Jun 2025 | $22.5B |
| Mar 2025 | $22.8B |
| Dec 2024 | $23.4B |
| Sep 2024 | $23.8B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+60.6%
TTM free cash flow over market value at close 2026-10-27
FCF yield BHC
| FY Dec 2025 | +39.0% |
| FY Dec 2024 | +42.5% |
| FY Dec 2023 | +27.9% |
| FY Dec 2022 | -41.6% |
| FY Dec 2021 | +11.7% |
| Jun 2026 | +77.7% |
| Mar 2026 | +51.4% |
| Dec 2025 | +39.0% |
| Sep 2025 | +45.9% |
| Jun 2025 | +45.3% |
| Mar 2025 | +51.5% |
| Dec 2024 | +42.5% |
| Sep 2024 | +35.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing BHC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $10.3B | $9.6B | $8.8B | $8.1B |
| Operating income | $1.8B | $1.5B | $963.0M | $454.0M |
| Net income | $157.0M | -$46.0M | -$592.0M | -$225.0M |
| EPS (diluted) | 0.42 | -0.13 | -1.62 | -0.62 |
| Operating cash flow | $1.4B | $1.6B | $1.0B | -$728.0M |
| Cash | $1.3B | $1.2B | $947.0M | $564.0M |
| Long-term debt | $20.6B | $18.9B | $21.9B | $20.3B |
SEC XBRL, fiscal years, as known on 2026-10-28
BHC Stock Sonar score 6/7 axes
Find similar shapesCompareBHC ranks highest on profitability (83rd percentile) and financial health (76th), and lowest on insider conviction (26th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BHC filings, in plain words
Are Bausch Health Companies insiders buying or selling BHC?
In the 180 days to 2026-10-28, Bausch Health Companies insiders were net sellers, a net $391.7K across purchases and sales reported on Form 4, by 2 sellers.
Are there planned insider sales of BHC?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $258.9K of stock; the latest, by Lenar Aimee J., was filed 2026-08-19.
Read the full summary
In the 180 days to 2026-10-28, Bausch Health Companies insiders were net sellers of BHC, a net $391.7K across purchases and sales reported on Form 4 by 2 sellers. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $258.9K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
